Bioactive-coated implants in trauma surgery

European Journal of Trauma and Emergency Surgery

Volumn 34, Issue 1, 2008, Pages 60-68

  Fuchs, Thomas ^a   Schmidmaier, Gerhard ^b   Raschke, Michael J ^a   Stange, Richard ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antibiotics; Coating; Growth factors; Implants; Trauma surgery

Indexed keywords

EID: 41249087149     PISSN: 18639933     EISSN: 16153146     Source Type: Journal    
DOI: 10.1007/s00068-006-6110-5     Document Type: Article

References (27)

1. Einhorn TA, Lane JM. Significant advances have been made in the way surgeons treat fractures [editorial]. Clin Orthop 1998;(355 Suppl): S2-S3.
2. Taylor CJ, Bannister GC, Calder S. Perioperative wound infection in elective orthopaedic surgery [published erratum appears in J Hosp Infect 1991 Feb;17:155]. J Hosp Infect 1990;16:241-47.
3. Coventry M, Nolan D, Bukenbauch R. "Delayed" prophylactic anticoagulation: a study of results and complications in 2,012 total hip arthroplasties. J Bone Joint Surg 1973;55:1487-92.
4. Einhorn TA. Enhancement of fracture healing. J Bone Joint Surg Am 1995;77:940-56.
5. Schmidmaier G, Wildemann B, Stemberger A, Haas NP, Raschke M. Biodegradable poly(D,L-lactide) coating of implants for continuous release of growth factors. J Biomed Mater Res Appl Biomat 2001;58:449-55.
6. Yasko AW, Lane JM, Fellinger EJ, Rosen V, Wozney JM, Wang EA. The healing of segmental bone defects, induced by recombinant human bone morphogenetic protein (rhBMP-2). A radiographic, histological, and biomechanical study in rats. J Bone Joint Surg Am 1992;74:659-70.
7. Raschke M, Kolbeck S, Ball H, Schmidmaier C, Flyvbjerg A, Lindner T, Dahne M, Roenne I, Haas N. Homologous growth hormone accelerates healing of segmental bone defects. Bone 2001;29:368-73.
8. Raschke MJ, Bail H, Windhagen HJ, Kolbeck SF, Weiler A, Raun K, Kappelgard A, Skiaerbaek C, Haas NP. Recombinant growth hormone accelerates bone regenerate consolidation in distraction osteogenesis. Bone 1999;24:81-8.
9. Li RH, Wozney JM. Delivering on the promise of bone morphogenetic proteins. Trends Biotechnol 2001;19:255-65.
10. Lucke M, Schmidmaier C, Sadoni S, Wildemann B, Schiller R, Haas N, Raschke. Gentamicin coating of metallic implants reduces implant related osteomyelitis in rats. Bone 2003;32:521-31.
11. Raschke M, Wildemann B, Inden P, Bail H, Flyvbjerg A, Hoffmann J, Haas NP, Schmidmaier G. Insulin-like growth factor-1 and transforming growth factor-betai accelerates osteotomy healing using polylactide-coated implants as a delivery system: a biomechanical and histological study in minipigs. Bone 2002;30:144-51.
12. Fujimoto R, Tanizawa T, Nishida S, Yamamoto N, Soshi S, Endo N, Takahashi HE. Local effects of transforming growth factorbetai on rat calvarla: changes depending on the dose and the injection site. J Bone Miner Metab 1999;17:11-17.
13. Zheng MH, Wood DJ, Papadimitriou JM. What's new in the role of cytokines on osteoblast proliferation and differentiation? Pathol Res Pract 1992;188:1104-21.
14. Sumner DR, Turner TM, Purchio AF, Combotz WR, Urban RM, Calante JO. Enhancement of bone ingrowth by transforming growth factor-beta. J Bone Joint Surg Am 1995;77:1135-47.
15. Schmidmaier G, Wildemann B, Bail H, Lucke M, Fuchs T, Stemberger A, Flyvbjerg A, Haas NP, Raschke M. Local application of growth factors (insulin-like growth factor-1 and transforming growth factor-β1) from a biodegradable poly(D,L-lactide) coating of osteosynthetic implants accelerates fracture healing in rats. Bone 2001;28:341-50.
16. Kandziora F, Pflugmacher R, Scholz M, Schäfer J, Schollmeier C, Schmidmaier G, Duda C, Raschke M, Haas NP. Dose-dependent effects of combined ICF-I and TCF-β1 application in a sheep cervical spine fusion model. Eur Spine J 2003;12:464-73.
17. Kandziora F, Bail H, Schmidmaier G, Schollmeier C, Scholz M, Knispel C, Hiller T, Pflugmacher R, Mittlmeier T, Raschke M, Haas NP. Bone morphogenic protein-2 application by a poly (D,L-lactide)-coated interbodycage: in vivo results of a new carrier for growth factors. J Neurosurg (Spine 1) 2002;97:40-8.
18. Kandziora F, Schmidmaier C, Schollmeier C, Bail H, Pflugmacher R, Corke T, Wagner M, Raschke M, Mittlmeier T, Haas NP. ICF-I and TGF-betai application by a poly-(D,L-lactide)-coated cage promotes intervertebral bone matrix formation in the sheep cervical spine. Spine 2002;27:1710-23.
19. Beck A, Kinzl L, Bischoff M. Antibiotic prophylaxis and therapy in trauma surgery. Unfallchirurg 1999;102:955-66.
20. Sanderson PJ. Preventing infection in orthopaedic implants. J Antimicrob Chemother 1989;24:277-80.
21. Southorn PA, Plevak DJ, Wright AJ, Wilson WR. Adverse effects of vancomycin administered in the perioperative period. Mayo Clin Proc 1986;61:721-4.
22. Suter F, Avai A, Fusco U, Gerundini M, Caprioli S, Maggiolo F. Teicoplanin versus cefamandole in the prevention of Infection in total hip replacement. Eur J Clin Microbiol Infect Dis 1994;13:793-6.
23. Wall R, Klenerman L, McCullough C, Fyfe I. A comparison of teicoplanin and cefuroxime as prophylaxis for orthopaedic implant surgery: a preliminary report. J Antimicrob Chemother 1988;21(Suppl A), 141-46.
24. Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin [see comments] [published erratum appears in J Antimicrob Chemother 1996 Nov;38(5):919 and 1997 Jul;40:147]. J Antimicrob Chemother 1996;37:209-22.
25. Cristina AG, Costerton JW. Bacterial adherence to biomaterials and tissue. T 1985;67:264-73.
26. Littlewood EA, Hattenberger M, Zak O, O'Reilly T. Effect of combination therapy of rifampidn and azithromycin on TNF levels during a rat model of chronic osteomyelitis. J Antimicrob Chemother 1997;39:493-98.
27. Lucke M, Schmidmaier G, Sadoni S, Wildemann B, Schiller R, Stemberger A, Haas N, Raschke M. A new model of implant related osteomyelitis in rats. J Biomed Mater Res 2003;67B:593-602.